Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe plus rosuvastatin versus rosuvastatin alone after PCI in acute coronary syndrome
ChiCTR-IPR-17012219Phase 4Recruiting
- Sponsor
- Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, China
- Start
- Aug 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ezetimibe and rosuvastatin in acute coronary syndrome (ACS) (2 arms), sponsored by Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, China. Primary endpoints: sPLA2-IIa, IL-1β and 2 more. Started Aug 2017; status: recruiting.
02
Drugs
ezetimiberosuvastatin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR-IPR-17012219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012219.